MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.…
MYND Life Sciences (CNSX: MYND) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0700 CAD on 19 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 0.0700 CAD to 0.0700 CAD, and it trades at the top of that range.
Its market capitalisation is 3.35M CAD.
MYND Life Sciences reports return on equity of 30.5%.
Its debt exceeds its cash by 3.00M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.